Huntington Disease – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Huntington Disease

Huntington’s Disease – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Huntington disease (HD) is a brain disease that is passed down in families from generation to generation. HD causes deterioration in a person’s physical, mental, and emotional abilities, usually during their prime working years, and currently has no cure. Most people start developing symptoms during adulthood, between the ages of 30 to 50, but HD can also occur in children and young adults (known as juvenile HD or JHD). HD is known as a family disease because every child of a parent with HD has a 50/50 chance of inheriting the faulty gene. Huntington disease (HD) is caused by a change (mutation) in the HTT gene. This gene gives instructions for making a protein called huntingtin. The HTT gene mutation that causes HD involves a DNA segment known as a CAG trinucleotide repeat.

Types of Huntington's Disease

Huntington's disease has two subtypes:

Adult-onset Huntington's disease- This is the most common form of Huntington's disease. People with adult-onset Huntington's disease usually develop symptoms in their mid-40s and 50s.

Juvenile Huntington's disease- Children and teenagers have this form of Huntington's disease, which is very rare. Children with Huntington's disease often have symptoms similar to Parkinson's disease. They may also develop problems with schoolwork.

Epidemiology- according to Thelansis about 42,000 people in the United States have Huntington’s disease and another 220,000 are at risk of developing the condition.

Competitive landscape of Huntington Disease includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Huntington Disease across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Huntington Disease Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Huntington Disease – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

S. No        Asset        Company        Partner        Phase

1        Xenazine        Bausch Health Companies Inc.        Lundbeck        Approved (Generic Competition)

2        Austedo        Teva Pharmaceutical Industries Ltd.        N/A        Approved

3        Ingrezza        Neurocrine Biosciences, Inc.        Mitsubishi Tanabe Pharma        III

4        Tominersen        Roche Holding AG        Ionis Pharmaceuticals        III

5        Neflamapimod        EIP Pharma, Inc.        Vertex Pharmaceuticals        II

6        Pepinemab        Vaccinex, Inc.        N/A        II

7        SEN196        AOP Orphan Pharmaceuticals AG        Elixir Pharmaceuticals; Siena Biotech        II

8        TV-7820        Prilenia Therapeutics Development Ltd.        NeuroSearch        II

9        AMT-130        uniQure N.V.        N/A        I/II

10        SRX246        Azevan Pharmaceuticals        N/A        I/II

11        WVE-120101        WAVE Life Sciences Ltd.        Takeda Pharmaceutical        I/II

12        WVE-120102        WAVE Life Sciences Ltd.        Takeda Pharmaceutical        I/II

13        NP03        Medesis Pharma SA        N/A        I

14        SAGE-718        Sage Therapeutics, Inc.        N/A        I

15        T3D-959        T3D Therapeutics, Inc.        Bayer; Midatech        I

16        ANX-005        Annexon, Inc.        N/A        IND

17        Cannabinoid Program (Scythian)        SOL Global Investments Corp.        N/A        IND

18        Dojolvi        Ultragenyx Pharmaceutical Inc.        Baylor Research Institute; Uniquest        Investigator Initiated

19        GSK-2245840        GlaxoSmithKline plc        N/A        Investigator Initiated

20        SBT-20        Stealth BioTherapeutics Inc.        N/A        Status to confirm

21        SOM3355        SOM Biotech        Nippon Chemiphar        Status to confirm

22        AON Program (Vico)        Vico Therapeutics        N/A        Preclinical

23        BCR159        BioCrea GmbH        N/A        Preclinical

24        BV-CYP01        BrainVectis        N/A        Preclinical

25        EHP-102        Emerald Health Pharmaceuticals Inc.        N/A        Preclinical

26        HTT Program (Exicure)        Exicure, Inc.        N/A        Preclinical

27        Huntington's Disease Program (CHDI/Evotec)        Evotec SE        CHDI Foundation        Preclinical

28        INT41        Vybion Inc.        N/A        Preclinical

29        mAB C6-17        AFFiRiS GmbH        N/A        Preclinical

30        MMJ-002        MMJ Group Holdings Ltd        N/A        Preclinical

31        MP101        Mitochon Pharmaceuticals, Inc.        N/A        Preclinical

32        NLS-12        NLS Pharmaceutics AG        N/A        Preclinical

33        NT0100        NeuBase Therapeutics, Inc.        N/A        Preclinical

34        NurOwn        BrainStorm Cell Therapeutics Inc.        N/A        Preclinical

35        ReN001        ReNeuron Group plc        Fosun Pharma        Preclinical

36        RT001 (Retrotope)        Retrotope, Inc.        N/A        Preclinical

37        S107        ARMGO Pharma, Inc.        N/A        Preclinical

38        Small Molecule Program (PTC/CHDI Foundation)        PTC Therapeutics, Inc.        CHDI Foundation        Preclinical

39        TTX-3360        Triplet Therapeutics, Inc.        N/A        Preclinical

40        VY-HTT01        Voyager Therapeutics, Inc        Sanofi; CHDI Foundation        Preclinical

41        WVE-003        WAVE Life Sciences Ltd.        Takeda Pharmaceutical        Preclinical

42        ZFP TF - Huntingtin Repressor        Sangamo Therapeutics, Inc.        Takeda Pharmaceutical        Preclinical